Impaired endothelial antithrombotic activity following short-term interruption of continous subcutaneous insulin infusion in type I diabetic patients

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 635-641

  Iorio, Alfonso ^a   Federici, Marco Orsini ^a   Mourvaki, Evangelia ^a   Ferolla, Piero ^a   Piroddi, Marta ^a   Stabile, Anna ^a   Timi, Alessandra ^a   Celleno, Roberta ^a   Benedetti, Massimo Massi ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Diabetes mellitus; Fibrinolysis; Hyperketonemia; Oxidative stress; PAI I

Indexed keywords

3 HYDROXYBUTYRIC ACID; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; GLUCOSE; INSULIN; MALONALDEHYDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ANTIGEN DETECTION; ARTERY THROMBOSIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTHROMBIN TIME; REVIEW; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ADULT; BLOOD COAGULATION TESTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FACTOR VII; FACTOR VIII; FEMALE; FIBRINOLYSIS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CARBONYLATION; THROMBOPLASTIN; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 34548683467     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-03-0201     Document Type: Review

References (48)

1. Miles JM, Rizza RA, Haymond MW, et al. Effects of acute insulin deficiency on glucose and ketone body turnover in man: evidence for the primacy of overproduction of glucose and ketone bodies in the genesis of diabetic ketoacidosis. Diabetes 1980; 29: 926-930.
2. Schade DS, Eaton RP. The regulation of plasma ketone body concentration by counter-regulatory hormones in man. III. Effects of norepinephrine in normal man. Diabetes 1979; 28: 5-10.
3. Vignati L, Asmal AC, Black WL, et al. Coma in diabetes. In: Joslin's Diabetes Mellitus. Lea & Febiger, Philadelphia, 1985: 526-552.
4. Clement S, Braithwaite SS, Magee MF, et al American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553-591.
5. Silverstein J, Klingensmith G, Copeland K, et al. American Diabetes Association. Care of children and adolescents with type I diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28: 186-212.
6. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
7. Fattah MA, Shaheen MH, Mahfouz MH. Disturbances of haemostasis in diabetes mellitus. Dis Markers 2003; 19: 251-258.
8. Berrettini M, Parise P, Ricotta S, et al. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 plynsaturated fatty acid supplementation in patients with chronic atherosclerotic disease. Thromb Haemost 1996; 75: 395-400.
9. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years. Thromb Haemost 2006; 95: 49-55.
10. Hoekstra T, Geleijnse JM, Schouten EG, et al. Plasminogen activator inhibitor-type I: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-872.
11. Thorand B, Baumert J, Doting A, et al. Association of cardiovascular risk factors with markers of endothelial dysfunction in middle-aged men and women. Results from the MONICA/KORA Augsburg Study. Thromb Haemost 2006; 95: 134-141.
12. Parise P, Hauert J, Iorio A, et al. Fibrinogen degradation products generation is the major determinant of platelet inhibition induced by plasminogen activators in platelet rich plasma. Fibrinolysis 1993; 7: 379-385.
13. Van der Meijden PE, Feijge MA, Giesen PL, et al. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005; 93: 1128-1136.
14. el Khawand C, Jamart J, Donckier J, et al. Hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care 1993; 16: 1137-1145.
15. Thogersen AM, Jansson JH, Boman K. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
16. Vericel E, Januel C, Carreras M, et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 2004; 53: 1046-1051.
17. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001; 15: 203-210.
18. Ileri NS, Buyukasik Y, Karaahmetoglu S, et al. Evaluation of the haemostatic system during ketoacidotic deterioration of diabetes mellitus. Haemostasis 1999; 29: 318-325.
19. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
20. Krzentowski G, Scheen A, Castillo M, et al. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 1983; 24: 314-318.
21. Castillo MJ, Scheen AJ, Lefebvre PJ. The degree/ rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose level. J Clin Endocrinol Metab 1996; 81: 1975-1978.
22. Guerci B, Meyer L, Salle A, et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999; 84: 2673-2678.
23. Guerci B, Benichou M, Floriot M. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care 2003; 26: 1137-1141.
24. Wieczorek I, Ludlam CA, MacGregor I. Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells - the importance of consensus on the use of correction factors for haemo-concentration. Thromb Haemost 1993; 69: 91-93.
25. Levine RL, Williams JA, Stadtman ER, et al. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994; 233: 346-357.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
27. Fukunaga K, Takama K, Suzuki T. High-performance liquid chromatographic determination of plasma malondialdehyde level without a solvent extraction procedure. Anal Biochem 1995; 230: 20-23.
28. Esterbauer H, Lang J, Zadravec S, et al. Detection of malonaldehyde by high-performance liquid chromatography. Methods Enzymol 1984; 105: 319-328.
29. Byrne HA, Tieszen KL, Hollis S, et al. Evaluation of an electrochemical sensor for measuring blood ketones. Diabetes Care 2000; 23: 500-503.
30. Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care 1999; 22 (Suppl 3): C14-20.
31. Orsini-Federici M, Akwi JA, Canonico V, et al. Early detection of insulin deprivation in continuous subcutaneous insulin infusion patients with type 1 diabetes. Diabetes Technol Ther 2006; 8: 67-75.
32. Davi G, Violi F, Catalano I, et al. Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. Blood Coagul Fibrinolysis 1991; 2: 41-45.
33. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003; 115 (Suppl 8): 62S-68S Abstract.
34. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
35. Maiello M, Boeri D, Podesta E et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992; 41: 1009-1015.
36. Pandolfi A, Iacoviello L, Capani F, et al. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia 1996; 39: 1425-1431.
37. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
38. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267.
39. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339-352.
40. Jain SK. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J Biol Chem 1989; 264: 21340-21345.
41. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173: 932-939.
42. Yim HS, Kang SO, Hah YC, et al. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem 1995; 270: 28228-28233.
43. Jain SK, Kannan K, Lim G. Ketosis (acetoacetate) can generate oxygen radicals and cause increased lipid peroxidation and growth inhibition in human endothelial cells. Free Radic Biol Med 1998; 25: 1083-1088.
44. Jain SK, McVie R. Hyperketonernia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients. Diabetes 1999; 48: 1850-1855.
45. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
46. Rajeswari P, Natarajan R, Nadler JL, et al. Glucose induces lipid peroxidation and inactivation of membrane-associated ion-transport enzymes in human erythrocytes in vivo and in vitro. J Cell Physiol 1991; 149: 100-109.
47. Jain SK. In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats. J Clin Invest 1985; 76: 281-286.
48. Ceriello A, Giacomello F, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44: 924-928.